Appleton Partners Inc. MA Sells 1,525 Shares of Edwards Lifesciences Corp (EW)

Appleton Partners Inc. MA Sells 1,525 Shares of Edwards Lifesciences Corp (EW)

Appleton Partners Inc. MA lowered its stake in Edwards Lifesciences Corp (NYSE:EW) by 13.1% during the first quarter, according to its most recent filing with the SEC. The firm owned 10,075 shares of the medical research company’s stock after selling 1,525 shares during the period. Appleton Partners Inc. MA’s holdings in Edwards Lifesciences Corp were worth $948,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tocqueville Asset Management L.P. boosted its position in shares of Edwards Lifesciences Corp by 69.8% in the third quarter. Tocqueville Asset Management L.P. now owns 155,229 shares of the medical research company’s stock worth $18,714,000 after buying an additional 63,810 shares during the last quarter. APG Asset Management N.V. boosted its position in shares of Edwards Lifesciences Corp by 4.7% in the third quarter. APG Asset Management N.V. now owns 363,625 shares of the medical research company’s stock worth $43,839,000 after buying an additional 16,300 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Edwards Lifesciences Corp by 11.6% in the third quarter. Wells Fargo & Company MN now owns 813,221 shares of the medical research company’s stock worth $98,042,000 after buying an additional 84,223 shares during the last quarter. BRC Investment Management LLC bought a new position in shares of Edwards Lifesciences Corp during the third quarter worth approximately $754,000. Finally, Scott & Selber Inc. boosted its position in shares of Edwards Lifesciences Corp by 0.6% in the third quarter. Scott & Selber Inc. now owns 20,741 shares of the medical research company’s stock worth $2,501,000 after buying an additional 123 shares during the last quarter. Hedge funds and other institutional investors own 83.99% of the company’s stock.

Edwards Lifesciences Corp (NYSE:EW) traded up 0.12% during trading on Friday, hitting $110.58. The company had a trading volume of 842,862 shares. The stock has a market capitalization of $23.35 billion, a price-to-earnings ratio of 36.76 and a beta of 0.53. Edwards Lifesciences Corp has a 1-year low of $81.12 and a 1-year high of $121.75. The company’s 50 day moving average price is $98.33 and its 200-day moving average price is $94.53.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Tuesday, April 25th. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.12. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. The business had revenue of $883.50 million for the quarter, compared to analyst estimates of $776.51 million. During the same period last year, the company earned $0.71 EPS. Edwards Lifesciences Corp’s revenue for the quarter was up 26.7% compared to the same quarter last year. On average, analysts expect that Edwards Lifesciences Corp will post $3.53 EPS for the current year.

A number of brokerages recently commented on EW. Vetr upgraded Edwards Lifesciences Corp from a “buy” rating to a “strong-buy” rating and set a $111.50 price target on the stock in a research report on Tuesday, March 28th. Royal Bank of Canada raised their price target on Edwards Lifesciences Corp from $116.00 to $120.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 26th. Cowen and Company restated an “outperform” rating and issued a $120.00 price target on shares of Edwards Lifesciences Corp in a research report on Tuesday, March 28th. Stifel Nicolaus raised their price target on Edwards Lifesciences Corp from $114.00 to $118.00 and gave the stock a “buy” rating in a research report on Wednesday, April 26th. Finally, Northland Securities restated a “positive” rating and issued a $105.00 price target on shares of Edwards Lifesciences Corp in a research report on Tuesday, February 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $118.59.

In related news, VP Donald E. Bobo, Jr. sold 34,120 shares of the firm’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $109.98, for a total transaction of $3,752,517.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 49,100 shares of the firm’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $89.63, for a total value of $4,400,833.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 250,910 shares of company stock worth $25,674,005. 2.37% of the stock is owned by corporate insiders.

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Related posts

Leave a Comment